<DOC>
	<DOCNO>NCT02747602</DOCNO>
	<brief_summary>To compare serum ketone body ( i.e. , total ketone β-hydroxybutyrate ) level administration AC-1204 versus caprylic triglyceride ( CT ) oil , standard breakfast . To evaluate effect high fat diet serum ketone body level administration CT oil high fat breakfast versus standard breakfast .</brief_summary>
	<brief_title>Evaluation PK AC1204 v Caprylic Triglyceride Oil Incl Food Effect Ketone Body Production</brief_title>
	<detailed_description />
	<criteria>1 . Healthy , adult , male 1855 year age , inclusive , screen . 2 . Continuous nonsmoker use nicotinecontaining product least 3 month prior first dose throughout study . 3 . Body mass index ( BMI ) ≥ 20.0 ≤ 30.0 kg/m2 screening . 4 . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign ECGs , deem PI designee . At screen , subject must alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) alkaline phosphatase ( ALP ) &lt; upper limit normal triglyceride level &lt; 250 mg/dL . 5 . A nonvasectomized subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 month prior first dose/dosing study drug . A subject vasectomized le 4 month prior study first dose/dosing must follow restriction nonvasectomized male ) . 6 . Subjects must agree donate sperm first dose/dosing 90 day dose . 7 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI designee . 3 . History illness , opinion PI designee , might confound result study pose additional risk subject participation study . 4 . History presence alcoholism drug abuse within past 2 year prior first dose/dosing . 5 . History presence hypersensitivity idiosyncratic reaction study drug , related compound , milk , coconut oil , soy . 6 . History presence diverticular disease , ulcer , inflammatory bowel disease recurrent diarrhea gout . 7 . Positive urine drug alcohol result screen checkin . 8 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) . 9 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 10 . Seated heart rate lower 40 bpm high 99 bpm screening . 11 . QTc interval &gt; 460 msec ( male ) ECG finding deem abnormal clinical significance PI designee screening . 12 . Estimated creatinine clearance ≤80 mL/min screening . 13 . Unable refrain anticipates use drug , include prescription nonprescription medication , herbal remedy , vitamin supplement begin 14 day prior first dose throughout study . Acetaminophen ( 2 g per 24 hour period ) medication treatment adverse event may permit study . 14 . Has diet incompatible onstudy diet , opinion PI designee , within 28 day prior first dose throughout study . 15 . Is lactose intolerant . 16 . Is unable complete critical meal ( i.e. , breakfast prior dose ) . 17 . Donation blood significant blood loss within 56 day prior first dose . 18 . Plasma donation within 7 day prior first dose . 19 . Participation another clinical study within 28 day prior first dose . The 28day window derive date last blood collection dosing , whichever later , previous study Day 1 Period 1 current study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Caprylic triglyceride oil</keyword>
	<keyword>AC-1204</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Ketone body</keyword>
</DOC>